DE69512760D1 - Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden - Google Patents

Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden

Info

Publication number
DE69512760D1
DE69512760D1 DE69512760T DE69512760T DE69512760D1 DE 69512760 D1 DE69512760 D1 DE 69512760D1 DE 69512760 T DE69512760 T DE 69512760T DE 69512760 T DE69512760 T DE 69512760T DE 69512760 D1 DE69512760 D1 DE 69512760D1
Authority
DE
Germany
Prior art keywords
melatonin
treat patients
drug addiction
addiction
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69512760T
Other languages
English (en)
Other versions
DE69512760T2 (de
Inventor
Nava Zisapel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Application granted granted Critical
Publication of DE69512760D1 publication Critical patent/DE69512760D1/de
Publication of DE69512760T2 publication Critical patent/DE69512760T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69512760T 1995-02-01 1995-06-06 Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden Expired - Lifetime DE69512760T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies

Publications (2)

Publication Number Publication Date
DE69512760D1 true DE69512760D1 (de) 1999-11-18
DE69512760T2 DE69512760T2 (de) 2000-05-31

Family

ID=23505399

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69512760T Expired - Lifetime DE69512760T2 (de) 1995-02-01 1995-06-06 Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden

Country Status (13)

Country Link
US (3) US6469044B1 (de)
EP (1) EP0724878B1 (de)
KR (1) KR100425045B1 (de)
AR (1) AR003921A1 (de)
DE (1) DE69512760T2 (de)
ES (1) ES2139842T3 (de)
HK (1) HK1001218A1 (de)
IL (1) IL114296A (de)
LT (1) LT4339B (de)
RO (1) RO116771B1 (de)
RU (1) RU2182001C2 (de)
UA (1) UA63878C2 (de)
ZA (1) ZA96548B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
IL130171A (en) * 1999-05-27 2004-06-01 Neurim Pharma 1991 Melatonin for use in preventing and treating tardive dyskinesia, pharmaceutical preparations containing it and its use in the manufacture of medicines
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6998112B2 (en) * 2003-03-18 2006-02-14 Arthur Zuckerman Sleep inducing toothpaste made with natural herbs and a natural hormone
MXPA06009377A (es) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
ES2673286T3 (es) 2011-02-11 2018-06-21 Zx Pharma, Llc Formulaciones multiparticuladas de L-mentol y métodos relacionados
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
JP5869735B2 (ja) 2013-04-23 2016-02-24 ズィーエックス ファーマ，エルエルシー 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
ES2828034T3 (es) 2016-10-31 2021-05-25 Neurim Pharma 1991 Minicomprimidos de melatonina y método de fabricación de los mismos
WO2024079125A1 (en) 2022-10-14 2024-04-18 Société des Produits Nestlé S.A. Sustained release melatonin compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
AU601736B2 (en) 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
US4800087A (en) 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5242941A (en) 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
ES2134789T3 (es) * 1991-05-09 1999-10-16 Neurim Pharma 1991 Composiciones que contienen melatonina.
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies

Also Published As

Publication number Publication date
RU2182001C2 (ru) 2002-05-10
UA63878C2 (en) 2004-02-16
KR19980701640A (ko) 1998-06-25
DE69512760T2 (de) 2000-05-31
IL114296A (en) 1999-10-28
US6833383B2 (en) 2004-12-21
KR100425045B1 (ko) 2004-09-01
IL114296A0 (en) 1995-10-31
US20020156121A1 (en) 2002-10-24
ZA96548B (en) 1996-08-14
LT4339B (lt) 1998-05-25
US20030040539A1 (en) 2003-02-27
RO116771B1 (ro) 2001-06-29
HK1001218A1 (en) 1998-06-05
EP0724878A2 (de) 1996-08-07
LT97135A (en) 1997-12-29
EP0724878A3 (de) 1996-08-21
EP0724878B1 (de) 1999-10-13
US6469044B1 (en) 2002-10-22
ES2139842T3 (es) 2000-02-16
AR003921A1 (es) 1998-09-30

Similar Documents

Publication Publication Date Title
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
DE69636883D1 (de) Vorrichtung zur Behandlung von Schlafapnoe durch elektrische Stimulation
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE69636674D1 (de) Vorrichtung zur wärmebehandlung von gewebe
DE69740073D1 (de) System zur modifikation von neuralem gewebe
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69630321D1 (de) Vorrichtung zur örtlichen wärmebehandlung von gewebe
DE69513672D1 (de) Verbesserte vorrichtung zur iontophoretischen verabreichung von medikamenten
ATE269077T1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
DE69621447D1 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition